Monarch Capital Management Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Monarch Capital Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 106.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,067 shares of the biopharmaceutical company’s stock after buying an additional 549 shares during the period. Monarch Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $760,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after purchasing an additional 11,499 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after buying an additional 2,270 shares in the last quarter. Finally, Swiss National Bank increased its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after buying an additional 2,000 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of research analyst reports. Evercore ISI dropped their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:REGN opened at $681.58 on Friday. The stock’s 50-day moving average is $738.60 and its 200 day moving average is $949.99. The company has a market cap of $74.90 billion, a PE ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.